MedTrace Logo

Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC)

NCT00419042 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2013-10-01

No results posted yet for this study

Summary

The purpose of this study is in non small-cell lung cancer stage IV et IIIB (T4 with pleural effusion) in elderly dependent patients with evaluation of the sequence Gemcitabine first line followed by Erlotinib when progression versus Erlotinib first line followed by Gemcitabine when progression

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

TARCEVA

Tarceva (150 mg) is a pill you take once a day -- every day -- to help treat non-small cell lung cancer.

DRUG

Gemzar

GEMZAR by mixing it into a solution and giving it through a needle into a vein-called intravenous infusion (IV). This will take about 30 minutes

Sponsors & Collaborators

  • Groupe Francais De Pneumo-Cancerologie

    lead OTHER

Principal Investigators

  • Hervé LECAER, Doctor · Groupe Francais De Pneumo-Cancerologie

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2006-09-30
Completion
2010-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00419042 on ClinicalTrials.gov